<DOC>
	<DOCNO>NCT02083250</DOCNO>
	<brief_summary>The goal clinical research study evaluate safety combine vorinostat ( also call SAHA ) fludarabine , clofarabine , busulfan .</brief_summary>
	<brief_title>Fludarabine/Clofarabine/Busulfan Combined With SAHA Acute Leukemia</brief_title>
	<detailed_description>Study Groups : All participant receive dose level fludarabine , clofarabine , busulfan . You assign dose level vorinostat base join study . Up 6 dose level vorinostat may test . Up 3 participant may enrol dose level . The first group participant receive first dose level vorinostat . Each new group receive high dose group , intolerable side effect see . When high tolerate dose level find , participant may enrol level . For stem cell transplant , day receive stem cell call minus day . The day receive stem cell call Day 0 . The day receive stem cell call plus day . Study Drug Administration Procedures : All group receive `` test '' dose busulfan vein 45 minute 1 hour . This low-level test dose busulfan check fast busulfan process body clear blood . This information determine amount busulfan receive . You may receive busulfan test dose outpatient week admit hospital inpatient 8 day stem cell transplant . About 11 sample blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test . PK test measure amount study drug body different time point also help determine dose busulfan . These blood sample draw various time receive test dose busulfan next 11 hour . These blood draw repeat first day high-dose busulfan treatment ( Day -6 , 6 day transplant ) . A heparin lock line place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . On Days -6 -3 , receive vorinostat tablet mouth day , fludarabine vein 1 hour , clofarabine vein 1 hour , busulfan vein 3 hour . If go receive transplant HLA-matched unrelated donor , also receive antithymocyte globulin ( ATG ) vein 4 hour 3 day transplant . This drug design weaken immune system reduce risk reject transplant . You give standard drug help decrease risk side effect . You may ask study staff information drug give risk . While hospital , check side effect part standard care . Blood ( 2 teaspoon ) draw every day check side effect , routine test , check blood count , kidney liver function , check infection . Tests may repeat , doctor think need . As part standard care , remain hospital 3-4 week transplant . After release hospital , must remain Houston area monitor infection transplant side effect 3 month transplant . During time , return clinic least 1 time week . The following test procedure perform : Â°Blood ( 2 teaspoon ) draw routine test . Around 14-30 day transplant ( transplant `` engrafts '' , `` take '' ) , bone marrow aspirate check status disease . To collect bone marrow aspirate , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . Around Day 30 , ALL , lumbar puncture check status disease . To perform lumbar puncture ( also call spinal tap ) , special needle insert low back space bone . The needle use draw sample fluid surround spinal cord . Around Day 30 , 3 , 6 , 12 month transplant , follow test procedure perform : - You physical exam . - Blood ( 2 teaspoon ) drawn see well transplant take . - You bone marrow aspiration check status disease . After first year transplant end participation study , study staff may also call local doctor ask health . This call may take 10 minute . Length Study : You take study 5 year end treatment . You may take study early disease get bad , intolerable side effect , stem cell transplant `` take '' , disease relapse ( return ) , unable follow study direction . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Fludarabine , clofarabine , vorinostat FDA approve commercially available treatment cancer . Busulfan also FDA approve use stem cell transplant . The use drug together stem cell transplant investigational . The study doctor explain study drug design work . Up 72 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients biopsyproven acute lymphoblastic leukemia , acute myeloid leukemia , myelodysplastic syndrome remission relapse . 2 . Estimated creatinine clearance least 50 ml/min . 3 . Bilirubin equal less 1.5 ( unless Gilbert 's Syndrome ) , SGPT &lt; 3 X upper limit normal alkaline phosphatase &lt; 2 X upper limit normal . 4 . Pulmonary function FEV1 , FVC DLCO least 45 % expect corrected hemoglobin . Children unable perform pulmonary function must oxygen saturation great 92 % room air . 5 . Adequate cardiac function leave ventricular ejection fraction least 45 % appropriate medical therapy . No uncontrolled arrhythmias symptomatic cardiac disease . 6 . Zubrod performance status 01 Lansky/Karnofsky PS equal great 80 % . 7 . Patients must relate , genotypically HLA identical donor , must unrelated donor 8/8 HLA match high resolution type . 8 . Patient patient 's legal representative , parent ( ) guardian provide write informed consent . Assent minor participant 's age least seven less eighteen year . 9 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 1 . Patients active CNS disease . 2 . Evidence acute chronic active hepatitis cirrhosis . 3 . Uncontrolled infection , include HIV , HTLV1 , hepatitis B hepatitis C viremia . 4 . Patients great 60 yearsold . 5 . Prior allogeneic SCT . 6 . Prior autologous SCT last 12 month . 7 . Patients AML first remission one course induction favorable cytogenetics [ ( 8 ; 21 , inv 16 , ( 15 ; 17 ) ] and/or molecular profile ( NPM1 ) . 8 . Prior radiation liver form total body involved field .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Allogeneic stem cell transplant</keyword>
	<keyword>SCT</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Clolar</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>SAHA</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
</DOC>